SOLASODINE (cas 126-17-0) reverses stemness and epithelial-mesenchymal transition in human colorectal cancer

Add time:09/09/2019    Source:sciencedirect.com

Adverse side effects of conventional chemotherapy, acquired resistance and fatal tumor metastasis of human colorectal cancer (CRC) are propelling the exploration for novel selective anticarcinogens. SOLASODINE (cas 126-17-0) is a main active component isolated from Solanum incanum L that exhibited a potent stemness and invasion inhibitory effect on human colorectal cancer HCT116 cells. Colony Spheroid formation assay showed that solasodine dose-dependently prohibited HCT116 cell stemness. CD133, CD44, Nanog, Oct-4 and Sox-2 were inhibited by solasodine to reverse stemness and similar mechanism was stimulated in vivo. Transwell and scratch wound assays revealed that solasodine impeded HCT116 cell invasion and migration potential strengthened by TGF-β1. Moreover, solasodine attenuated TGF-β1-induced EMT and decreased MMPs while in vivo study showed the same trend. The results of this study implied that solasodine may be a novel therapeutic drug for CRC treatment.

We also recommend Trading Suppliers and Manufacturers of SOLASODINE (cas 126-17-0). Pls Click Website Link as below: cas 126-17-0 suppliers

Prev:Synergism of MGK-264 and piperonyl butoxide on the toxicity of plant derive molluscicides
Next:SOLASODINE (cas 126-17-0)-3-O-β-d-glucopyranoside is hydrolyzed by a membrane glucosidase into active molecule SOLASODINE (cas 126-17-0) against Candida albicans)